FDA ends CSR pilot, plots new approach for disclosing study reports
The FDA on Thursday officially ended a fledgling pilot program that was part of an effort to provide more transparency on the drug approval process …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
